Bepirovirsen

Bepirovirsen is an antisense medicine for chronic hepatitis B. Ionis Pharmaceuticals discovered it and licensed it to GSK in 2019; GSK runs its development, regulatory filings and commercialization, and Ionis receives royalties. The next event is the FDA decision on Bepirovirsen, on Oct 26, 2026 (source).

Company: Ionis Pharmaceuticals (IONS) · Discovered it; licensed to GSK
How it works: HBV antisense oligonucleotide
Approved: Not approved in any market we track

Development by disease

Chronic hepatitis b

Filed

Upcoming events

Firm dates · a specific day set by the company or regulator

Next 30 days

Oct 26
in 13 days
Bepirovirsen · FDA decision · Chronic hepatitis B
Ionis Pharmaceuticals (IONS)·Source

Past results and milestones

May 28, 2026
B-Well 1 and B-Well 2 Phase 3 trials met primary and key secondary endpoints, demonstrating 19% functional cure rate in overall population (vs. 0% placebo, p<0.001) and 26% in patients with lower viral activity subgroup. Regulatory submissions expected Q3 2026. Source

Trials

The investment thesis, what each upcoming event depends on and the competitive landscape are on the Ionis Pharmaceuticals page. Upcoming FDA decisions · All drugs